Event submissions
Published
This submission belongs to the session Session C. Cancer Immunology and Immunotherapy of the event The 4th International Electronic Conference on Cancers
Published date
27 Mar, 2024
Academic Editor
'%3e%3cpath%20d='M12.6657%2010.9104C12.4185%2010.325%2012.0599%209.79327%2011.6097%209.34482C11.1609%208.89508%2010.6293%208.5365%2010.0442%208.28888C10.0389%208.28626%2010.0337%208.28495%2010.0285%208.28233C10.8446%207.69279%2011.3752%206.73249%2011.3752%205.64904C11.3752%203.8542%209.92103%202.39999%208.1262%202.39999C6.33136%202.39999%204.87715%203.8542%204.87715%205.64904C4.87715%206.73249%205.40774%207.69279%206.22393%208.28364C6.21869%208.28626%206.21345%208.28757%206.20821%208.29019C5.62129%208.5378%205.09463%208.89284%204.64265%209.34613C4.1929%209.79493%203.83432%2010.3266%203.58671%2010.9117C3.34345%2011.4845%203.21226%2012.0987%203.20023%2012.7209C3.19988%2012.7349%203.20233%2012.7488%203.20744%2012.7619C3.21255%2012.7749%203.22022%2012.7867%203.22998%2012.7968C3.23975%2012.8068%203.25142%2012.8147%203.26431%2012.8202C3.2772%2012.8256%203.29105%2012.8284%203.30504%2012.8284H4.09109C4.14874%2012.8284%204.19459%2012.7825%204.1959%2012.7262C4.2221%2011.7148%204.62823%2010.7676%205.34617%2010.0497C6.08899%209.30683%207.0755%208.89808%208.1262%208.89808C9.17689%208.89808%2010.1634%209.30683%2010.9062%2010.0497C11.6242%2010.7676%2012.0303%2011.7148%2012.0565%2012.7262C12.0578%2012.7838%2012.1037%2012.8284%2012.1613%2012.8284H12.9474C12.9613%2012.8284%2012.9752%2012.8256%2012.9881%2012.8202C13.001%2012.8147%2013.0126%2012.8068%2013.0224%2012.7968C13.0322%2012.7867%2013.0398%2012.7749%2013.0449%2012.7619C13.0501%2012.7488%2013.0525%2012.7349%2013.0522%2012.7209C13.0391%2012.0947%2012.9094%2011.4855%2012.6657%2010.9104ZM8.1262%207.9024C7.52486%207.9024%206.9589%207.6679%206.53312%207.24211C6.10733%206.81633%205.87283%206.25037%205.87283%205.64904C5.87283%205.0477%206.10733%204.48174%206.53312%204.05596C6.9589%203.63018%207.52486%203.39567%208.1262%203.39567C8.72753%203.39567%209.29349%203.63018%209.71927%204.05596C10.1451%204.48174%2010.3796%205.0477%2010.3796%205.64904C10.3796%206.25037%2010.1451%206.81633%209.71927%207.24211C9.29349%207.6679%208.72753%207.9024%208.1262%207.9024Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Vasso ApostolopoulosCitation
Nyanbol Kuol, Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines, in Proceedings of The 4th International Electronic Conference on Cancers, 6 March–8 March 2024, MDPI: Basel, Switzerland
Share
Email
FaceBook
Twitter
Linkedin
Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines
'%3e%3cpath%20d='M12.6647%2010.9104C12.4176%2010.325%2012.0589%209.7933%2011.6088%209.34485C11.16%208.89511%2010.6283%208.53653%2010.0432%208.28891C10.038%208.28629%2010.0327%208.28498%2010.0275%208.28236C10.8437%207.69282%2011.3743%206.73252%2011.3743%205.64907C11.3743%203.85423%209.92005%202.40002%208.12522%202.40002C6.33038%202.40002%204.87618%203.85423%204.87618%205.64907C4.87618%206.73252%205.40677%207.69282%206.22296%208.28367C6.21772%208.28629%206.21248%208.2876%206.20724%208.29022C5.62031%208.53783%205.09365%208.89287%204.64167%209.34616C4.19192%209.79496%203.83334%2010.3266%203.58573%2010.9117C3.34247%2011.4846%203.21128%2012.0987%203.19925%2012.721C3.1989%2012.735%203.20135%2012.7489%203.20646%2012.7619C3.21157%2012.7749%203.21924%2012.7868%203.22901%2012.7968C3.23877%2012.8068%203.25045%2012.8148%203.26334%2012.8202C3.27623%2012.8256%203.29007%2012.8284%203.30406%2012.8284H4.09012C4.14776%2012.8284%204.19362%2012.7825%204.19493%2012.7262C4.22113%2011.7148%204.62726%2010.7676%205.34519%2010.0497C6.08802%209.30686%207.07452%208.89811%208.12522%208.89811C9.17592%208.89811%2010.1624%209.30686%2010.9052%2010.0497C11.6232%2010.7676%2012.0293%2011.7148%2012.0555%2012.7262C12.0568%2012.7839%2012.1027%2012.8284%2012.1603%2012.8284H12.9464C12.9604%2012.8284%2012.9742%2012.8256%2012.9871%2012.8202C13%2012.8148%2013.0117%2012.8068%2013.0214%2012.7968C13.0312%2012.7868%2013.0389%2012.7749%2013.044%2012.7619C13.0491%2012.7489%2013.0515%2012.735%2013.0512%2012.721C13.0381%2012.0947%2012.9084%2011.4856%2012.6647%2010.9104ZM8.12522%207.90243C7.52388%207.90243%206.95792%207.66793%206.53214%207.24215C6.10636%206.81636%205.87185%206.2504%205.87185%205.64907C5.87185%205.04773%206.10636%204.48177%206.53214%204.05599C6.95792%203.63021%207.52388%203.3957%208.12522%203.3957C8.72655%203.3957%209.29252%203.63021%209.7183%204.05599C10.1441%204.48177%2010.3786%205.04773%2010.3786%205.64907C10.3786%206.2504%2010.1441%206.81636%209.7183%207.24215C9.29252%207.66793%208.72655%207.90243%208.12522%207.90243Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Nyanbol Kuol 1
1. University of Nevada, Reno
Abstract
Keywords
PD-L1
M3R
ChAT
CRC
Colorectal cancer
cholinergic markers
immunosuppresive markers
immune